Target Price | €159.00 |
Price | €110.35 |
Potential | 44.09% |
Number of Estimates | 16 |
16 Analysts have issued a price target Merck 2026 . The average Merck target price is €159.00. This is 44.09% higher than the current stock price. The highest price target is €195.00 76.71% , the lowest is €107.00 3.04% . | |
A rating was issued by 18 analysts: 15 Analysts recommend Merck to buy, 2 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Merck stock has an average upside potential 2026 of 44.09% . Most analysts recommend the Merck stock at Purchase. |
15 Analysts have issued a sales forecast Merck 2025 . The average Merck sales estimate is €21.6b . This is 1.41% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €22.1b 3.83% , the lowest is €21.4b 0.22% .
This results in the following potential growth metrics:
2024 | €21.2b | 0.78% |
---|---|---|
2025 | €21.6b | 2.17% |
2026 | €22.5b | 4.10% |
2027 | €23.3b | 3.46% |
2028 | €24.4b | 4.89% |
2029 | €25.6b | 5.03% |
15 Analysts have issued an Merck EBITDA forecast 2025. The average Merck EBITDA estimate is €6.1b . This is 3.88% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €6.3b 7.00% , the lowest is €5.7b 2.41% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €4.9b | 3.42% |
---|---|---|
2025 | €6.1b | 23.91% |
2026 | €6.5b | 6.98% |
2027 | €6.9b | 5.11% |
2028 | €7.3b | 6.22% |
2029 | €7.8b | 6.51% |
2024 | 23.31% | 2.62% |
---|---|---|
2025 | 28.27% | 21.29% |
2026 | 29.05% | 2.76% |
2027 | 29.51% | 1.58% |
2028 | 29.88% | 1.25% |
2029 | 30.30% | 1.41% |
12 Merck Analysts have issued a net profit forecast 2025. The average Merck net profit estimate is €3.0b . This is 8.13% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €3.3b 18.38% , the lowest is €2.7b 2.46% .
This results in the following potential growth metrics and future Net Margins:
2024 | €2.8b | 1.66% |
---|---|---|
2025 | €3.0b | 9.68% |
2026 | €3.4b | 10.98% |
2027 | €3.6b | 7.01% |
2028 | €3.8b | 5.91% |
2029 | €4.1b | 7.68% |
2024 | 13.13% | 2.42% |
---|---|---|
2025 | 14.09% | 7.34% |
2026 | 15.02% | 6.60% |
2027 | 15.54% | 3.46% |
2028 | 15.69% | 0.97% |
2029 | 16.08% | 2.49% |
12 Analysts have issued a Merck forecast for earnings per share. The average Merck EPS is €7.01 . This is 8.18% higher than earnings per share in the financial year 2024. The highest EPS forecast is €7.67 18.36% , the lowest is €6.32 2.47% .
This results in the following potential growth metrics and future valuations:
2024 | €6.39 | 1.69% |
---|---|---|
2025 | €7.01 | 9.70% |
2026 | €7.77 | 10.84% |
2027 | €8.32 | 7.08% |
2028 | €8.81 | 5.89% |
2029 | €9.49 | 7.72% |
Current | 17.03 | 35.97% |
---|---|---|
2025 | 15.75 | 7.51% |
2026 | 14.19 | 9.90% |
2027 | 13.26 | 6.55% |
2028 | 12.52 | 5.58% |
2029 | 11.63 | 7.11% |
Based on analysts' sales estimates for 2025, the Merck stock is valued at an EV/Sales of 2.57 and an P/S ratio of 2.25 .
This results in the following potential growth metrics and future valuations:
Current | 2.61 | 32.03% |
---|---|---|
2025 | 2.57 | 1.39% |
2026 | 2.47 | 3.94% |
2027 | 2.39 | 3.34% |
2028 | 2.28 | 4.67% |
2029 | 2.17 | 4.79% |
Current | 2.28 | 34.63% |
---|---|---|
2025 | 2.25 | 1.39% |
2026 | 2.16 | 3.94% |
2027 | 2.09 | 3.35% |
2028 | 1.99 | 4.66% |
2029 | 1.89 | 4.79% |
Analyst | Rating | Action | Date |
---|---|---|---|
REDBURN ATLANTIC |
Buy
➜
Buy
|
Unchanged | Apr 06 2025 |
DZ BANK |
Buy
➜
Buy
|
Unchanged | Apr 01 2025 |
DAY BY DAY |
Sell
➜
Sell
|
Unchanged | Mar 30 2025 |
HSBC |
Buy
➜
Buy
|
Unchanged | Mar 23 2025 |
EQUITA SIM |
Buy
➜
Buy
|
Unchanged | Mar 16 2025 |
ODDO BHF |
Buy
➜
Buy
|
Unchanged | Mar 10 2025 |
JEFFERIES |
Buy
➜
Buy
|
Unchanged | Mar 05 2025 |
Analyst Rating | Date |
---|---|
Unchanged
REDBURN ATLANTIC:
Buy
➜
Buy
|
Apr 06 2025 |
Unchanged
DZ BANK:
Buy
➜
Buy
|
Apr 01 2025 |
Unchanged
DAY BY DAY:
Sell
➜
Sell
|
Mar 30 2025 |
Unchanged
HSBC:
Buy
➜
Buy
|
Mar 23 2025 |
Unchanged
EQUITA SIM:
Buy
➜
Buy
|
Mar 16 2025 |
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Mar 10 2025 |
Unchanged
JEFFERIES:
Buy
➜
Buy
|
Mar 05 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.